Biomarkers associated with checkpoint inhibitors
Guillaume Manson, J. Norwood, Aurélien Marabelle et al. · Annals of Oncology · 2016
Cited by 164 works. doi:10.1093/annonc/mdw181
Authors
References
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- The blockade of immune checkpoints in cancer immunotherapy
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Signatures of mutational processes in human cancer